drugset
drugset / Trial / NCT00726583

Phase I Trial of Oral PX-866

NCT00726583 ↗

Phase 1 Completed 90 enrolled Cascadian Therapeutics Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is being conducted to determine the safety and maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.

Timeline

Start
2008-06
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject SONOLISIB Small molecule — Oral

Indications

cancer